A significant landmark towards 𝐂𝐮𝐫𝐞𝐒𝐢𝐠𝐡𝐭™ of Novasight

创建时间:2021-08-25 09:00

 

Exactly a year after kicking off the randomized controlled pivotal study of our 𝐂𝐮𝐫𝐞𝐒𝐢𝐠𝐡𝐭™ eye tracking based lazy eye treatment system, we are thrilled to announce that we have completed enrollment of the 83rd patient and passed the required number of enrolled patients needed for reaching the trial’s first readout (interim) point! This marks a significant landmark towards 𝐂𝐮𝐫𝐞𝐒𝐢𝐠𝐡𝐭™ FDA 510(K) clearance as potentially the only approved device to replace the patch and our path to commercialization in the US.

The clinical trial is taking place in 6 different medical centers across Israel, including Sheba Tel HaShomer City of Health, ranked as one of the top 10 best hospitals in the world.

We wish to thank the clinical teams that have worked hard to reach this point and strengthen their hands on the way to completing enrolment of the 90th patient. 

Sheba Tel HaShomer City of Health Rambam Health Care Campus Soroka Medical Center Maccabi Health care Services

Prof. Tamara Wygnanski-Jaffe, Prof. Abraham Spierer, Prof. Hana Leiba, Dr. Eedy Mezer, Dr. Idit Keinan, Dr. Ronen Rabinowitz, Dr. Ohad Amtirat, Dr. Chiya Barret.

 

 

 

 

 

 

睿盟希国际视觉科学基金,以 For better vision and insight 为愿景,致力于全球范围内挖掘并投资视觉科学领域的创新科技公司

我们专注于细分领域跨境投资、并购、

商务合作和技术转移

欢迎扫描二维码关注